Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3 Lymphoid 2 Other solid neoplasm 1 Gynecologic 1 Breast 1

Conditions

Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1

Interventions

Paclitaxel 100 Trastuzumab 81 pembrolizumab 78 Fulvestrant 68 Cyclophosphamide 66 Carboplatin 49 Capecitabine 47 Docetaxel 45 palbociclib 41 Lapatinib 40 Letrozole 37 Doxorubicin 29 olaparib 28 Taxes 28 Nivolumab 25 Magnetic Resonance Spectroscopy 25 Gemcitabine 25 130-nm albumin-bound paclitaxel 25 Everolimus 23 Biopsy 23 ribociclib 22 abemaciclib 21 Specimen Handling 21 Albumin-Bound Paclitaxel 21 Cisplatin 20 Radiotherapy 19 Bevacizumab 19 Ado-Trastuzumab Emtansine 19 pertuzumab 17 Alpelisib 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Drug Evaluation × Breast × Clear all

NCT03236974 2020-02-06

D6090C00002

AstraZeneca

Phase 1 Completed

Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡